Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapy.

ABSTRACT: Low hemoglobin values are associated with cardiotoxicity in patients with melanoma and other cancer entities receiving immune checkpoint inhibitor (ICI) therapy. However, in cancer patients under chemotherapy, enhanced incidence of cardiotoxicity events are also reported with increasing hemoglobin values. So far, the association between hemoglobin values within the normal limits and the incidence of cardiotoxicity in melanoma patients treated with ICI therapy has not been examined. We analyzed 114 melanoma patients receiving ICI therapy (61 ± 13 years; 38 % female) from the prospective Essen Cardio-Oncology Registry (EcoR). Patients with cancer-related anemia (hemoglobin < 11 g/dL) were excluded from the analysis. Baseline hemoglobin levels were assessed at patient enrollment before initia

SUBMITTER: Haj-Yehia E 

PROVIDER: S-EPMC12368969 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature